title: Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
authors: R
authors: R
authors: Ordemann
authors: J
authors: J
authors: Stöhlmacher
authors: B
authors: B
authors: Beuthien-Baumann
authors: I
authors: I
authors: Platzek
authors: J
authors: J
authors: van den Hoff
authors: F
authors: F
authors: Kroschinsky
authors: J M
authors: JM
authors: Middeke
authors: U
authors: U
authors: Platzbecker
authors: C
authors: C
authors: Zietz
authors: M
authors: M
authors: Bornhäuser
authors: G
authors: G
authors: Ehninger
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002330:Carmustine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D057176:Compassionate Use Trials; D000077547:Crizotinib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D017710:Lymphocyte Transfusion; D017728:Lymphoma, Large-Cell, Anaplastic / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000032:analysis / Q000037:antagonists & inhibitors*; D036102:Peripheral Blood Stem Cell Transplantation; D011241:Prednisone / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors*; D012074:Remission Induction; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000209:etiology / Q000628:therapy; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018796:Immunoconjugates; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D003561:Cytarabine; D000077547:Crizotinib; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D000079963:Brentuximab Vedotin; D004317:Doxorubicin; D003520:Cyclophosphamide; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; D002945:Cisplatin; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone